People · Operator
Named in public records as an officer, director or promoter · active 2008–2019 · Biotechnology, Pharmaceuticals, Healthtech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Novus Therapeutics, Inc. | — | Biotechnology | Series D+ | $226.8M | $576.2M | 2009 |
| TScan Therapeutics, Inc. | — | Biotechnology | Series C | $123.3M | $3.3B | 2019 |
| Aileron Therapeutics Inc | — | Biotechnology | Series B | $111.3M | $173.1M | 2009 |
| Alios Biopharma Inc | — | Pharmaceuticals | Series C | $82.3M | $1.4B | 2008 |
| Icebreaker Health, Inc. | — | Healthtech | Series B | $51.5M | $890.1M | 2017 |
| Euthymics Bioscience, Inc. | — | Biotechnology | Series B | $31.3M | $11.9M | 2017 |
| Akebia Therapeutics, Inc. | — | Biotechnology | Series A | $25.9M | $504.1M | 2011 |
| Biorelix Inc | — | Pharmaceuticals | Series A | $15.9M | $79.2M | 2009 |
| Renovacor, Inc. | — | Biotechnology | Seed | $6.3M | $62.1M | 2019 |
Campbell Murray at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Campbell Murray on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.